Clarithromycin and azithromycin

Infectious Diseases in Clinical Practice

Volumn 5, Issue 5, 1996, Pages 291-302

  Barza, Michael ^a,c   Eisenberg, Ellen ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Box 41 ^*

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 HYDROXYCLARITHROMYCIN; ANTICONVULSIVE AGENT; AZITHROMYCIN; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450; DIGOXIN; ERYTHROMYCIN; MACROLIDE; RIFABUTIN; TERFENADINE; THEOPHYLLINE; ZIDOVUDINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; RASH; REVIEW;

EID: 0029737842     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199606000-00003     Document Type: Review

References (114)

1. Eisenberg E, Barza M. Azithromycin and clarithromycin. Curr Clin Top Infect Dis 1994;14:52-79.
2. Fass R. Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross resistance. Antimicrob Agents Chemother 1993;37:2080-6.
3. Hardy D. Extent and spectrum of the antimicrobial activity of clarithromycin. Pediatr Infect Dis J 1993;12:S99-S105.
4. Neu H. The development of macrolides: clarithromycin in perspective. Antimicrob Agents Chemother 1991;27: S1-S9.
5. Agacfidan A, Moneada J, Schacter J. In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumonlae. Antimicrob Agents Chemother 1993;37:1746-8.
6. Butler J, Breiman R, Faclam R. Emergence of drug-resistant pneumococci in the United States. In: Proceedings and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC): American Society for Microbiology, 1993:1182.
7. Lonks J, Medeiros A. High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I. Antimicrob Agents Chemother 1993;37:1742-5.
8. Hooton T. A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis. Am J Med 1991;91:S23-S26.
9. Naik S, Ruck R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother 1989;33:1614-6.
10. Cynamon M, Klemens S, Grossi M. Comparative activities of azithromycin and clarithromycin against Mycobacterium avinm infection in beige mice. Antimicrob Agents Chemother 1994;38:1452-4.
11. Heifets L, Mor N, Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother 1993;37:2364-70.
12. Klemens S, Cynamon M. Activities of azithromycin and clarithromycin against nontuberculous mycobacteria. Antimicrob Agents Chemother 1994;38:1455-9.
13. Dever L, Jorgensen J, Barbour A. Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. Antimicrob Agents Chemother 1993;37:1704-6.
14. Alder J, Mitten M, Jaris K, Gupta P, Clement J. Efficacy of clarithromycin for the treatment of experimental Lyme disease in vivo. Antimicrob Agents Chemother 1993;37: 1329-33.
15. Lukehart S, Fohn M, Baker-Zander S. Efficacy of azithromycin for therapy of active syphilis in the rabbit model. J Antimicrob Chemother 1990;25:91-9.
16. Alder J, Jarvis K, Mitten M, Shipkowitz N, Gupta P, Clement J. Clarithromycin therapy of experimental Treponema pallidum infections in hamsters. Antimicrob Agents Chemother 1993;37:864-7.
17. Maurin M, Raoult D. In vitro susceptibilities of spotted fever group Rickettsia and Coxiella burnetii to clarithromycin. Antimicrob Agents Chemother 1993;37:2633-7.
18. Araujo F, Prokocimer P, Lin T, et al. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. Antimicrob Agents Chemother 1992;36:2454-7.
19. Cantin L, Chamberland S. In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii. Antimicrob Agents Chemother 1993;37:1993-6.
20. Weiss L, Wittner M, Wasserman S, Oz H, Retsema J, Tanowitz H. Efficacy of azithromycin for treating Babesia microti infection in the hamster model. J Infect Dis 1993;168:1289-92.
21. Anderson S, Ager A, McGreevy P, Schuster B, Ellis W, Berman J. Efficacy of azithromycin as a causal prophylactic agent against murine malaria. Antimicrob Agents Chemother 1994;38:1862-93.
22. Le Clercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991;35:1267-72.
23. Sanchez M, Flint K, Jones R. Occurrence of macrolidelincosamide-streptogramin resistances among staphylococcal clinical isolates at a university medical center. Diagn Microbiol Infect Dis 1993;16:205.
24. Hardy D, Guay D, Jones R. Clarithromycin, a unique macrolide. Diagn Microbiol Infect Dis 1988;15:39-53.
25. Drew R, Gallis H. Azithromycin-spectrum of activity, pharmacokinetics, and clinical applications. Pharmacotherapy 1992;12:161-73.
26. Odenholt-Tomqvist I, Lowdin E, Cars O. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory pathogens. Antimicrob Agents Chemother 1995;39:221-6.
27. Le Bel M. Comparative pharmacokinetics of new macrolides. Can J Infect Dis 1993:4:149.
28. Chu S, Park B, Locke C, Wilson D, Cavanaugh J. Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 1992;32:32-6.
29. Piscitelli S, Danziger L, Rodvold K. Clarithromycin and azithromycin;new macrolide antibiotics. Clin Pharm 1992;11:137-52.
30. Foulds G, Shepard R, Johnson R. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25:273-82.
31. Biaxin Product Information [package insert].
32. Tatum WO, Gonzalez, MA. Carbamazepine toxicity in an epileptic induced by clarithromycin. Hosp Pharm 1994;29:45-6.
33. Chu S, Deaton R, Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 1992;36:1147-50.
34. Chu S, Wilson D, Guay D. Clarithromycin pharmacokinetics in health young and elderly volunteers. J Clin Pharmacol 1992:32:1045-9.
35. Bahal N, Nahata M. The new macrolide antibiotics azithromycin, clarithromycin, dirthromycin, and roxithromycin. Ann Pharmacother 1992;26:46-55.
36. Schentag J, Ballow C. Tissue directed pharmacokinetics. Am J Med 1991;91:S3-S11.
37. Guay D, Craft J. Overview of the pharmacology of clarithromycin suspension in children and comparison with that in adults. Pediatr Infect Dis J 1993:12:5106-5111.
38. Barza M. Challenges to antibiotic activity in tissue. Clin Infect Dis 1994;19:910-5.
39. Van den Broek PJ. Antimicrobial drugs, microorganisms and phagocytes. Rev Infect Dis 1989;11:213-45.
40. Schwab J, Cao Y, Slowik M, Joiner K. Localization of azithromycin in Toxoplasma gondii infected cells. Antimicrob Agents Chemother 1994:38:1620-7.
41. Martin D, Mroczkowski T, Dalu Z, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. N Engl J Med 1992; 327:921-5.
42. Mantides A, Xynos E, Chrysos E, et al. The effect of erythromycin in gastric emptying of solids and hypertonic liquids in healthy subjects. Am J Gastroenterol 1993;88:198-202.
43. Wallace R, Tanner D, Brennan P, Brown B. Clinical trial of clarithromycin for cutaneous infection due to Mycobacterium chelonae. Ann Intern Med 1993;119:482-6.
44. Anastasio G, Little J, Robinson M, Pettice Y, Leitch B, Norton H. Impact of compliance and side effects on the clinical outcome of patients treated with oral erythromycin. Pharmacotherapy 1994;14:229-34.
45. deVega T, Blanco S, Lopez C, Pascual E, Sanchez M, Zamarron A. Clarithromycin-induced leukocytoclastic vasculitis. Eur J Clin Microbiol Infect Dis 1993;12:563.
46. Brown BA, Wallace RJ Jr, Griffith DE, Girard W. Clarithromycin-induced hepatotoxicity. Clin Infect Dis 1995; 20:1073-4.
47. Mansoor G, Panner B. Ornt D. Azithromycin induced acute interstitial nephritis. Ann Intern Med 1993;119:636.
48. Honig P, Wortham D, Zamani K, Cantilena L. Effect of erythromycin, clarithromycin and azithromycin on the pharmacokinetics of terfenadine. Clin Pharmacol Ther 1993;53:161.
49. DA TRI 001 Study Group. Coadministration of clarithromycin alters the concentration time profile of rifabutin. In: Proceedings and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC): American Society for Microbiology, 1994:A2.
50. Berry A, Koletar S, Williams D. Azithromycin therapy for disseminated Mycobacterium avium-intracellulare in AIDS patients. In: Proceedings and abstracts of the First National Conference on Human Retroviruses and Related Infections. Washington (DC): 1993:291.
51. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for M. intracellulare infection. J Infect Dis 1995;171:747-50.
52. Ferrari SL, Goffin E, Mourad M, Wallemacq P, Squifflet J-P, Pirson Y. The interaction between clarithromycin and cyclosporine in kidney transplant recipients. Transplantation 1994;58:725-7.
53. Wolter, K, Wagner K, Philipp T, Fritschka E. Interaction between FK506 and clarithromycin in a renal transplant patient. Eur J Clin Pharmacol 1994;47:207-8.
54. Gustavson L, Chu J. Drug interactions between clarithromycin and oral zidovidine in HIV-1 infected patients [abstract]. Clin Pharmacol Ther 1993;53:PI-114.
55. Petty B, Polis M, Haneiwich S, Dellerson M, Draft JC, Chaisson R. Pharmacokinetic assessment of clarithromycin plus zidovudine in HIV patients. In: Proceedings and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Anaheim (CA). Washington (DC): American Society for Microbiology, 1992:24.
56. Vance E, Guzman J, Kazanjian P. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Poster Session, Tenth International Conference on AIDS; Yokahama, Japan:1994.
57. Husson RN, Ross LA, Sandelli S, et al. Orally administered clarithromycin for the treatment of systemic Mycobacterium avium complex infection in children with acquired immunodeficiency syndrome. J Pediatr 1994; 124:807-14.
58. Chave J, Munafo A, Chatton J, Dayer P, Glauser M, Biollaz J. Once a week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovidine disposition. Antimicrob Agents Chemother 1992;36:1013-8.
59. Rapeport W, Dewland P, Muirhead D, Forster P. Lack of an interaction between azithromycin and carbamazepine. In: Proceedings and abstracts of the British Pharmacological Society, Clinical Pharmacology Section. London: University College/Sandoz Institute for Medical Research, 1991:551P.
60. Harris S, Morse I, Hilligoss D, Colangelo, P, Eller, M. Azithromycin and terfenadine: lack of drug interaction, a double blind, placebo controlled study. In: Proceedings and abstracts of the 35th Interscience Conference Antimicrobial Agents and Chemotherapy. Washington (DC): American Society for Microbiology, 1993:597.
61. Amachev D, Schomaker S, Retsema J. Comparison of the effects of the new azalide antibiotic, azithromycin and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother 1991;35:1186-90.
62. Gardner M, Coates P, Hilligoss D, Henry E. Lack of effect of azithromycin on the pharmacokinetics of theophyline in man. In: Proceedings and abstracts of the 8th Mediterranean Conference on Chemotherapy. Athens (Greece), 1992:136.
63. Pozzi E, Grossi E, Pecori A. Azithromycin vs. clarithromycin in the treatment of acute exacerbations of chronic bronchitis. Curr Ther Res Clin Exp 1994:55:759-64.
64. Levenstein J. Clarithromycin vs. penicillin in the treatment of streptococcal pharyngitis. J Antimicrob Chemother 1991;27:S67-S74.
65. Bachand R. Comparative study of clarithromycin and ampicillin in the treatment of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1991;27:91-100.
66. Schrock C. Clarithromycin vs. penicillin in the treatment of streptococcal pharyngitis. J Fam Pract 1992;35:622-6.
67. Still J, Hubbard W, Poole J, Sheaffer C, Chartrand S, Jacobs R. Comparison of clarithromycin and penicillin VK suspensions in the treatment of children with streptococcal pharyngitis and review of currently available alternative antibiotic therapies. Pediatr Infect Dis J 1993; 12:5134-5141.
68. Pichichero M, Margolis, P. A comparison of cephalosporins and penicillins in the treatment of group A betahemolytic streptococcal pharyngitis: a meta-analysis supporting the concept of microbial copathogenicity. Pediatr Infect Dis J 1991;10:275-81.
69. Karma P, Pukander J, Penttila M, et al. The comparative efficacy and safety of clarithromycin and amoxacillin in the treatment of outpatients with acute maxillary sinusitis. J Antimicrob Chemother 1990;27:S83-S90.
70. Casiano P. Azithromycin and amoxacillin in the treatment of acute maxillary sinusitis. Am J Med 1991;25: S27-S30.
71. Dubois J, St. Pierre C, Tremblay C. Efficacy of clarithromycin vs. amoxacillin/clavulanate in the treatment of acute maxillary sinusitis. Ear Nose Throat J 1993;72:804-10.
72. Pukander J, Jero J, Kapno E, Kaprio E, Sorri M. Clarithromycin vs. amoxacillin suspensions in the treatment of pediatric patients with acute otitis media. Pediatr Infect Dis J 1993;12:S118-S121.
73. McCarty J, Phillips A, Wiisanen R. Comparative safety and efficacy of clarithromycin and amoxacillin/clavulanate in the treatment of acute otitis media in children. Pediatr Infect DisJ 1993;12:S122-S127.
74. Gooch W, Can V, Corder W, Khurana C, Andrews W. Clarithromycin and cefaclor suspensions in the treatment of acute otitis media in children. Pediatr Infect Dis J 1993;12:S128-S133.
75. Aldons P. A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother 1991;27:S101-S108.
76. Wettengel R. Comparison of clarithromycin and cefaclor in the treatment of mild to moderate bronchitis. In: Proceedings and abstracts of the First International Conference on the Macrolides, Azalides, and Streptogramins. Santa Fe (NM), 1992.
77. Dark D. Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections. Am J Med 1991;91:531-5.
78. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 1995;273:957-60.
79. Davies B, Maesen F, Gubbelmans R. Azithromycin (CP-62:993) in acute exacerbations of chronic bronchitis: an open clinical, microbiological and pharmacokinetic study. J Antimicrob Chemother 1989;23:743-51.
80. Anderson G, Esmonde T, Coles S, et al. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. J Antimicrob Chemother 1991;27:117-24.
81. Kinasewitz G, Wood R. Azithromycin vs. cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1991:10:872-7.
82. Hamedani P, Ali J, Hafeez S, et al. The safety and efficacy of clarithromycin in patients with legionella pneumonia. Chest 1991;100:1503-6.
83. Myburgh J, Nagel G, Petschel E. The efficacy and tolerance of a three day course of azithromycin in the treatment of community acquired pneumonia. J Antimicrob Chemother 1993;31:163-9.
84. Schonwald S, Gunjaca M, Kolacny L, Car V, Gosev M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother 1990;25:123-6.
85. Gupta S, Siepman H. Comparative safety and efficacy of clarithromycin vs. standard agents in the treatment of mild to moderate bacterial skin or skin structure infections. In: Proceedings and abstracts of the First International Conference on the Macrolides, Azalides, and Streptogramins. Santa Fe (NM), 1992.
86. Hegert A, Still J, Reuman P. Comparative safety and efficacy of clarithromycin and cefadroxil suspensions in the treatment of mild to moderate skin and skin structure infections in children. Pediatr Infect Dis J 1993;12: S112-S117.
87. Kiani R. Double blind, double dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structure infections. Eur J Clin Microbiol Infect Dis 1991:10:880-4.
88. Steingrimsson O, Olafsson J, Thorarinsson H, Ryan R, Johnson R, Tilton R. Azithromycin in the treatment of sexually transmitted disease. J Antimicrob Chemother 1990;25:S109-S114.
89. Handsfield H, Dalu Z, Martin D, Douglas J, McCarty J, Schlossberg D. Multicenter trial of single dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Sex Transm Dis 1994;21:107-111.
90. Tribble D, Girgis N, Habib N, Butler T. Efficacy of azithromycin for typhoid fever. Clin Infect Dis 1995;21: 1045-6.
91. Barradell L, Polsker G, McTarish D. Clarithromycin, a review of its pharmacological properties and therapeutic use in Mycobacterium avium intracellulare complex infection in patients with AIDS. Drugs 1993;46:289-312.
92. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. Ann Intern Med 1994;121:905-11.
93. Dautzenberg B, Truffot C, Legris S, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with AIDS. Am Rev Respir Dis 1991:144: 564-9.
94. Dautzenberg B, St. Marc T, Chauvin J-P, et al. Clarithromycin in AIDS patients with disseminated M. avium infection. In: Proceedings and abstracts of the First International Conference on the Macrolides, Azalides, and Streptogramins. Santa Fe (NM), 1992.
95. Young L, Wiviott L, Wu M, et al. Azithromycin for the treatment of Mycobacterium avium intracellulare complex infection in patients with AIDS. Lancet 1991;338: 1107-9.
96. Currier J. Progress report. Prophylaxis and therapy for MAC. AIDS Clin Care 1996;8:45-8.
97. Pierce M, LaMarca A, Jablonowski H, et al. A placebo controlled trial of clarithromycin prophylaxis against MAC infection in AIDS patients. In: Proceedings and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; Orlando (FL). Washington (DC): American Society for Microbiology, 1994:A2.
98. Special report: recommendations in prophylaxis and therapy for disseminated M. avium complex disease in patients infected with HIV. N Engl J Med 1993;329:898-904.
99. Goldberger M, Masur H. Clarithromycin therapy for Mycobacterium aviun complex disease in patients with AIDS: potential and problems. Ann Intern Med 1994; 121:974-5.
100. Bonnet E, Debat-Zoguereh D, Petit N, Ravaux I, Gallais H. Clarithromycin: A potent agent against infections due to Mycobacterium marinum. Clin Infect Dis 1994:18: 664-6.
101. Luna-Herrera J, Reddy VM, Daneluzzi D, Gangadharam PRJ. Antituberculosis activity of clarithromycin. Antimicrob Agents Chemother 1995:39:2692-5.
102. Truffot-Pernot C, Lounis N, Grosset JH, Ji B. Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;2827-8.
103. Chan G, Garcia-Ignacio B, Chavez V, et al. Clinical trial of clarithromycin for lepromatous leprosy. Antimicrob Agents Chemother 1994:38:515-7.
104. Godofsky E. Treatment of presumed cerebral toxoplasmosis with azithromycin. N Engl J Med 1994;330:575-6.
105. Fernandez-Martin J, Leport C, Morlat P, Meyohas M, Chauvin J, Vilde J. Pyrimethamine-clarithromycin in combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother 1991;35:2049-52.
106. Lacassin F, Schaffo D, Perronne C, et al. Clarithromycinminocycline combination as salvage therapy for toxoplasmosis in HIV infected patients. Antimicrob Agents Chemother 1995;39:276-6.
107. Raffi F. Breakthrough cerebral toxoplasmosis in patients with AIDS who are being treated with clarithromycin. Clin Infect Dis 1995;20:1076-7.
108. Weber K, Wilske B, Preac-Mursic R. Azithromycin vs. penicillin for the treatment of early Lyme borreliosis. Infection 1993;21:367-72.
109. Verdon M, Handsfield H, Johnson R. Pilot study of azithromycin for treatment of primary and secondary syphilis. Clin Infect Dis 1994;19:486-8.
110. Guerra L, Neira C, Boman D, et al. Rapid response of AIDS related bacillary angiomatosis to azithromycin. Clin Infect Dis 1993;17:264-6.
111. Kuschner R, Heppner D, Andersen S, et al. Azithromycin prophylaxis against a chloroquine resistant strain of Plasmodium falciparum. Lancet 1994;343:1396-7.
112. Bailey R, Arullendran P, Whittle H, Mabey D. Randomised controlled trial of single dose azithromycin in treatment of trachoma. Lancet 1993;342:453-6.
113. Glupczynski Y, Burett A. Failure of azithromycin to eradicate Campylobacter pylori from the stomach because of acquired resistance during treatment. Am J Gastroenterol 1990;85:98-9.
114. Al-Assi M, Ramirez F, Lew GM, Genta RM, Graham DY. Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. Am J Gastroenterol 1994;89:1203-8.